Table 1.

Patient characteristics

	Upfront Immunotherapy Group (range/ percent)	Historical Control Group	P value
Total number of patients	93	100	N/A
Age	64 (26-88)	65 (31-91)	0.4
Sex (female)	51 (55%)	42 (42%)	0.07
Disease burden   Widespread   Oligometastasis No metastasis (except for brain)	15 (16%) 21 (23%) 57 (61%)	20 (20%) 31 (31%) 49 (49%)	0.2
Primary tumor type   NSCLC   RCC   Melanoma   SCLC	76 (81.7%) 7 (7.5%) 8 (8.6%) 2 (2.2%)	81 (81.0%) 13 (13.0%) 4 (4.0%) 2 (2.0%)	0.4
Median number intracranial lesions	2 (1-22)	2 (1-9)	0.0015
Lowest SRS margin dose	18 (12.5-30)	20 (8-25)	0.2

NSCLC=Non-Small Cell Lung Cancer; RCC=Renal Cell Cancer; SCLC=Small Cell Lung Cancer

p-values are from Chi-square test or Kruskal-Wallis test